Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 15 July 2019, 14:40 HKT/SGT
Share:
    

Source: Singapore-MIT Alliance for Research and Technology (SMART)
MIT's research enterprise in Singapore launches new research group, boosting nation's cell therapies R&D
MIT's Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore's National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.

-- S$10 million a year to be invested in SMART CAMP in a multi-year effort
-- New interdisciplinary research group, SMART CAMP, will bring together 35 MIT and Singapore investigators
-- Complementary and integrated programme with Singapore's Agency for Science Technology and Research (A*STAR) cell manufacturing effort, supported by the National Research Foundation (NRF)
-- SMART CAMP deploys MIT's innovation methodologies in Singapore's thriving biopharmaceutical industry, tapping market potential of billions a year.

SINGAPORE, July 15, 2019 - (Media OutReach) - Cell therapies, where cellular material is injected, grafted or implanted into a patient to treat a range of illnesses and medical conditions, are a vital and integral component of medicine today - promising treatment of tissue degenerative diseases, cancer, and autoimmune disorders.

However, significant challenges currently exist to prevent its widespread adoption including problems such as safety, potency, efficacy, and costs. To overcome these challenges, the Singapore-MIT Alliance for Research and Technology (SMART), together with A*STAR Institutes and supported by the National Research Foundation (NRF), has launched a new national initiative in Singapore that deploys MIT's globally renowned applied innovation methodology combined with Singapore's dynamic and growing biopharmaceutical manufacturing industry.

As part of the national initiative in cell manufacturing, CAMP is a new interdisciplinary research group within SMART that will focus on ways to produce living cells as medicine delivered to humans, leading to improved health outcomes. The National Research Foundation will support this multi-million, multi-year project that will bring together 35 MIT and Singapore investigators. They will be recruited from researchers working in SMART and Singapore institutes including A*STAR, KK Women's and Children's Hospital, the National University Hospital and local universities. Investigators from MIT in Cambridge, Massachusetts will also be recruited to support the programme.

"This is a field that is ripe for innovation, and one which we believe will benefit from both MIT's and Singapore's strengths," said Eugene Fitzgerald, CEO and Director of SMART. "By applying our problem-solving research methodology, coupled with Singapore's well-established biopharmaceutical manufacturing ecosystem, we are confident that we will be able to achieve market-ready breakthroughs."

Since its inception in Singapore in 2007, SMART has pioneered innovations that have transformed and are transforming fields such as autonomous driving, agriculture, microelectronics, mechanics and microfluidics platforms for biology and medical diagnostics, and antimicrobial resistance.

SMART CAMP will be helmed by Professor Krystyn Van Vliet of MIT and Professor Hanry Yu of NUS and A*STAR. Professor Van Vliet is an engineer with expertise at the interface of materials, mechanics, and biological systems and is an experienced leader, currently serving as the Associate Provost and the Director of Manufacturing Innovation at MIT. Her current research stemming from earlier SMART collaborations is in clinical trials at the Singapore General Hospital, and the prior SMART team that she led has spun off several MedTech companies in Singapore.

Professor Van Vliet explained, "By addressing critical technology bottlenecks in how the next generation of personalised medicines is made, SMART CAMP researchers will help set the standards for innovating on quality by design. Imagine providing just the right living cells - the most sophisticated drug factories we know - to each patient, as quickly and safely as possible. Delivering on that promise requires exciting changes in the way we understand, engineer, measure, and select cells that offer a safe and effective medicine for that person's ailment. And that goal, in turn, benefits from this investment in the research and researchers that can transform the manufacturing and analytics of biopharma products."

Professor Yu is a physiologist with expertise interface between mechanobiology, biomaterials, imaging and AI-based data analytics. He is also a serial entrepreneur, recently forming six companies, and the founding member of the Mechanobiology Institute Research Centre of Excellence in Singapore.

"This programme integrates experts from various disciplines, training staff and students who can think through the translational pipelines from basic knowledge and technology into commercially viable and clinically relevant solutions", said Professor Yu.

"There is a global need for safe and cost-effective cell therapies," said Dr. Khiang Wee Lim, Executive Director of CREATE, NRF. "We believe that it is an area in which Singapore can provide innovation space and bring these transformational technologies to millions around the world. Advances in this area will also boost Singapore's biopharmaceutical industry, bringing innovations and helping gain a lead in this promising market that is estimated to be worth billions."

About Singapore-MIT Alliance for Research and Technology (SMART)

Singapore-MIT Alliance for Research and Technology (SMART) is MIT's Research Enterprise in Singapore, established by the Massachusetts Institute of Technology (MIT) in partnership with the National Research Foundation of Singapore (NRF) since 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore. Cutting-edge research projects in areas of interest to both Singapore and MIT are undertaken at SMART. SMART currently comprises an Innovation Centre and six Interdisciplinary Research Groups (IRGs): Antimicrobial Resistance (AMR), BioSystems and Micromechanics (BioSyM), Critical Analytics for Manufacturing Personalized-Medicine (CAMP), Disruptive & Sustainable Technologies for Agricultural Precision (DiSTAP), Future Urban Mobility (FM) and Low Energy Electronic Systems (LEES).

SMART research is funded by the National Research Foundation Singapore under the CREATE programme. For more information, please visit - http://smart.mit.edu

For media queries, please contact:
Andrew Wong
[email protected]
+65 91993623


July 15, 2019 14:40 HKT/SGT
Topic: Research and development
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
New Disinfectant Stops Spread of Virus, Including Coronavirus Strain from China  
Jan 24, 2020 12:00 HKT/SGT
DOCOMO Releases White Paper Promoting 6G Communication System  
Jan 24, 2020 11:00 HKT/SGT
Fashion Hong Kong arrives at New York Fashion Week  
Jan 24, 2020 11:00 HKT/SGT
NEC Develops Millimeter-wave Distributed Antenna Radio Unit Improving the Channel Quality for Indoor 5G Applications  
Jan 24, 2020 10:05 HKT/SGT
Former New York University President John Sexton will be Asian University for Women's 2020 Commencement Speaker; an Indian economist, a Pakistani actress, and a Swiss educator will receive honorary degrees  
Jan 23, 2020 21:00 HKT/SGT
Garuda Indonesia Appoints Irfan Setiaputra as CEO  
Jan 23, 2020 19:00 HKT/SGT
Nissin Foods Forms Joint Venture Company to Strengthen Distribution Platform in PRC Market  
Jan 23, 2020 17:45 HKT/SGT
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan  
Jan 23, 2020 14:57 HKT/SGT
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation  
Jan 23, 2020 14:46 HKT/SGT
Mitsubishi Corporation Participates in Vietnam's "Grand Park Project"  
Jan 23, 2020 11:39 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: